Contract loss due to changes in the terms of the partnership agreement
First written in FY2020. 2 of 4 entries say "Cited as achieved", first in FY2022. Latest entry: FY2023.
No other company in this theme has enough history to compare yet.
- FY2023Cited as achievedAnnual report
「Payment of contract loss △ 1,000」
The company paid ¥1,000 million in the current consolidated fiscal year relating to the contract loss arising from changes to the alliance agreement terms recognized in a prior fiscal year. This is not the recognition of a new contract loss. - FY2022Cited as achievedAnnual report
「Payment of contract loss △ 2,000」
The cash flow statement reports a payment of ¥2,000 million in the current consolidated fiscal year relating to the contract loss recognized in the previous consolidated fiscal year. No new contract loss has been recognized. - FY2021No impairment loss recognized in the current periodAnnual report
「In the previous consolidated fiscal year (from 1 April 2019 to 31 March 2020), the Company recognized a contract loss of ¥3,000 million arising from changes to the terms of an alliance agreement relating to the sale of certain ethical pharmaceuticals, made to avoid risks associated with changes in the business environment, as an extraordinary loss for the period. In the current consolidated fiscal year (from 1 April 2020 to 31 March 2021), there were no applicable items.」
The ¥3,000 million contract loss arising from changes to the agreement terms is restated as comparative information for the previous consolidated fiscal year and was not incurred in the current consolidated fiscal year. - FY2020First statedAnnual report
「The Company recognized a contract loss of ¥3,000 million arising from changes to the terms of an alliance agreement relating to the sale of certain ethical pharmaceuticals as an extraordinary loss for the current period.」
The company recognized a ¥3,000 million contract loss as an extraordinary loss for the current period in connection with changes to the terms of an alliance agreement relating to the sale of certain ethical pharmaceuticals.